Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Trial end date:
2020-09-10
Target enrollment:
Participant gender:
Summary
This was a single-arm, open-label, multi-center Phase 2 study in participants with
histologically documented CLL/SLL who have relapsed after or refractory to ≥ 1 prior
treatment regimen(s). The study is composed of an initial screening phase, a single-arm
treatment phase, and a follow-up phase.